Clinical Trial Update: Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT [Phase 3]

View source ↗

Summary

A phase 3 randomized trial evaluating albumin-bound paclitaxel as neoadjuvant therapy for triple-negative breast cancer is underway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)

Snippet

Sponsor: Shengjing Hospital | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING